阿替洛爾
Atenolol
Atenololum (ICI-66082)
別名: Tenormin · Atenololum · ICI-66082
由 VetSheet 獸醫團隊審訂更新於 2026年4月5日本內容以實證獸醫文獻為本
劑量為合格獸醫專業人員的臨床參考。請務必對照最新仿單及個別病患確認。
各物種劑量
🌎 NA — North America🌍 EU — Europe
狗
| 適應症 | 劑量 | 途徑 | 頻次 | 療程 | 地區 |
|---|---|---|---|---|---|
| Cardiac arrhythmias, obstructive heart disease, hypertension, myocardial infarction, etc. | 0.3-0.6 mg/kg PO q12h | PO | q12h | — | 🌎 NA |
| Moderate to severe sub-valvular aortic stenosis (SAS) | 0.5-1 mg/kg PO twice a day | PO | q12h | — | 🌎 NA |
| To attempt to decrease syncopal episodes associated with pulmonic stenosis | 0.25-1 mg/kg PO twice a day | PO | q12h | — | 🌎 NA |
| Hypertension | 0.25-1 mg/kg PO q12h | PO | q12h | — | 🌎 NA |
- Cardiac arrhythmias, obstructive heart disease, hypertension, myocardial infarction, etc.: For refractory VTach combine with mexiletine (5-8 mg/kg PO q8h)
貓
| 適應症 | 劑量 | 途徑 | 頻次 | 療程 | 地區 |
|---|---|---|---|---|---|
| Treatment of hypertension or cardiac conditions (e.g., hypertrophic cardiomyopathy) | 3 mg/kg PO q12h (or 6.25 -12.5 mg total dose) PO q12h | PO | q12h | — | 🌎 NA |
| Treatment of hypertension or cardiac conditions | 6.25-12.5 mg (total dose per cat) q12h | PO | q12h | — | 🌎 NA |
| Treatment of choice for hyperthyroid, hypertensive cats | 6.25-12.5 mg (total dose) PO q12-24h | PO | q12-24h | — | 🌎 NA |
- Treatment of choice for hyperthyroid, hypertensive cats: Beta-blockers are rarely sufficient alone to treat hypertension due to other causes.
雪貂
| 適應症 | 劑量 | 途徑 | 頻次 | 療程 | 地區 |
|---|---|---|---|---|---|
| Hypertrophic cardiomyopathy | 6.25 mg (total dose) PO once daily | PO | q24h | — | 🌎 NA |
| Hypertrophic cardiomyopathy | 3.13-6.25 mg (total dose) PO once daily | PO | q24h | — | 🌎 NA |
劑量為合格獸醫專業人員的臨床參考。請務必對照最新仿單及個別病患確認。
概覽
阿替洛爾（Atenolol）是一種心臟選擇性β-受體阻斷劑，主要用於控制小動物的全身性高血壓和心搏過速性心律不整。它常被用於患有肥厚性心肌病（HCM）且無併發肺水腫的貓咪，以減少動態性流出通道阻塞並改善舒張期充盈。
主要特點：
- 心臟選擇性： 在常規劑量下對β2受體的作用極小，因此對於患有氣喘或支氣管痙攣的病患，比非選擇性β-受體阻斷劑（如普萘洛爾）相對安全。
- 負性肌力作用： 對於鬱血性心衰竭（CHF）、腎衰竭或竇房結功能障礙的病患，必須極度謹慎使用。
- 代謝影響： 較高劑量可能會掩蓋甲狀腺功能亢進或低血糖的臨床症狀。它也可能引起高血糖或低血糖，因此在血糖不穩定的糖尿病患中需謹慎使用。
臨床要點： 與普萘洛爾不同，阿替洛爾具有高度水溶性。它的脂溶性低，這意味著它極少穿透血腦屏障，因此中樞神經系統（CNS）副作用（如嗜睡或抑鬱）顯著較少。由於它主要以原形經腎臟排泄，對於有顯著腎功能損害的病患可能需要調整劑量。
作用機轉
Atenolol acts as a competitive, relatively specific antagonist at β1-adrenergic receptors located primarily in the myocardium.
- Pathway: Blockade of β1-receptors → decreased intracellular cAMP → reduced intracellular calcium influx.
- Cardiovascular Effects: This leads to negative chronotropic (decreased sinus heart rate) and negative inotropic (decreased contractility) effects. It slows AV conduction, diminishes cardiac output at rest and during exercise, and significantly decreases myocardial oxygen demand.
- Blood Pressure: Reduces systemic blood pressure through decreased cardiac output and potentially decreased renin release from the kidneys.
- Selectivity Loss: At higher dosages, β1 specificity may be lost, leading to β2-receptor blockade (which can cause bronchoconstriction and peripheral vasoconstriction).
- Atenolol lacks intrinsic sympathomimetic activity (ISA) and membrane-stabilizing activity.
安全性與警告
禁忌症
- Overt heart failure
- Hypersensitivity to beta-blockers
- Greater than first-degree heart block
- Sinus bradycardia
- Cats with hypertrophic cardiomyopathy with accompanying pulmonary edema
不良反應
- Lethargy
- Hypotension
- Diarrhea
- Bradycardia
- Inappetence
- Depression
- Impaired AV conduction
- Worsening of heart failure
- Hypoglycemia
- Syncope
- Bronchoconstriction (rare at normal doses)
注意事項
Withdrawal Warning: Exacerbation of symptoms has been reported following abrupt cessation of beta-blockers. It is highly recommended to withdraw therapy gradually in patients who have been receiving the drug chronically.
- Renal Impairment: Use cautiously in patients with significant renal insufficiency as the drug is primarily excreted unchanged in the urine.
- Endocrine: Can mask clinical signs associated with hypoglycemia and thyrotoxicosis. Use cautiously in labile diabetic patients as it can cause hypo- or hyperglycemia.
- Cardiac: Use cautiously in patients with sinus node dysfunction. Non-specific beta-blockers are generally contraindicated in patients with CHF unless secondary to a tachyarrhythmia responsive to beta-blocker therapy.
藥物交互作用
Additive myocardial depression may occur with concurrent use.
Concurrent use should be done with caution due to additive negative inotropic effects, particularly in patients with preexisting cardiomyopathy or CHF.
Atenolol may exacerbate rebound hypertension after stopping clonidine therapy.
May increase the hypotensive effects of atenolol.
Concurrent use may exhibit enhanced hypotensive effects.
Potential for additive effects including hypotension and bradycardia.
May have their actions blocked by atenolol, and they may in turn reduce the efficacy of atenolol.
監測
- Cardiac function
- Pulse rate
- ECG (if necessary)
- Blood pressure (if indicated)
- Signs of toxicity (lethargy, hypotension, bradycardia)
藥物動力學
半衰期
吸收
Absorbed rapidly. Bioavailability is approximately 90% in cats, but only 50-60% in humans.
分佈
Very low protein binding (5-15%) and distributed well into most tissues. Low lipid solubility; only small amounts distribute into the CNS. Crosses the placenta and levels in milk are higher than those found in plasma.
代謝
Minimally biotransformed in the liver.
排除
40-50% is excreted unchanged in the urine and the bulk of the remainder is excreted in the feces unchanged (unabsorbed drug). Duration of beta blockade effect in cats persists for about 12 hours.
過量
Common clinical signs of overdose include lethargy and vomiting. Severe overdose represents extensions of the drug's pharmacologic effects: hypotension, bradycardia, bronchospasm, cardiac failure, hypoglycemia, and hyperkalemia.
Treatment:
- If recent oral ingestion: consider emptying the gut and administering activated charcoal.
- Monitor: ECG, blood glucose, potassium, and blood pressure.
- Cardiovascular support: Symptomatic treatment. Use fluids and pressor agents (dopamine or norepinephrine) for hypotension.
- Bradycardia: Treat with atropine. If atropine fails, isoproterenol given cautiously is recommended.
- Metabolic: Insulin and dextrose may be needed for hyperkalemia and hypoglycemia.
- Advanced support: A transvenous pacemaker may be necessary. Cardiac failure can be treated with a digitalis glycoside, diuretics, and oxygen.
- Antidote: Glucagon (5-10 mg IV; human dose) may increase heart rate and blood pressure and reduce the cardiodepressant effects of atenolol.
可用產品
劑型
- Oral tablets
- Oral suspension (compounded)
人用標示
- Atenolol Oral Tablets: 25 mg, 50 mg, & 100 mg; Tenormin® (AstraZeneca); generic; (Rx)
- Also available in an oral fixed dose combination product with chlorthalidone.
各地核准狀態
暫無法規資料: 🇺🇸 US · 🇪🇺 EU · 🇬🇧 UK · 🇭🇰 HK · 🇹🇼 TW · 🇯🇵 JP · 🇰🇷 KR · 🇦🇺 AU
儲存與穩定性
Tablets should be stored at room temperature and protected from heat, light, and moisture. Atenolol preparations are most stable at pH 4 and should be protected from ultraviolet light to prevent decomposition. Compounding Note: Atenolol oral suspensions should NOT be compounded with sugar-containing vehicles (like simple syrup), as sugars reduce potency to <90% within 7-14 days. Suspensions compounded with sugar-free vehicles (Ora-Plus/Ora-Sweet SF) retain >90% potency for 90 days at 5°C and 25°C.
飼主須知
- 按時服藥： 為了發揮療效，您的寵物必須完全按照獸醫的指示服用所有劑量。
- 切勿突然停藥： 在未諮詢獸醫的情況下，絕對不要突然停止使用此藥物，因為這可能會導致心跳和血壓出現危險的飆升。如果需要停藥，必須逐漸減量。
- 觀察副作用： 如果您的寵物變得異常嗜睡、表現出運動不耐、出現呼吸急促或咳嗽，或者行為或態度發生突然改變，請立即通知您的獸醫。
- 藥錠分割： 根據指示，可以將藥錠壓碎或切成四分之一或一半以達到適當的劑量。
VetSheet 藥物參考供合格獸醫專業人員作臨床決策輔助之用，不能取代專業判斷或廠商最新仿單。